The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 12, 2024
Filed:
Apr. 08, 2019
Eisai R&d Management Co., Ltd., Tokyo, JP;
Gregg F. Keaney, Lexington, MA (US);
John Wang, Andover, MA (US);
Baudouin Gerard, Belmont, MA (US);
Kenzo Arai, Ibaraki, JP;
Xiang Liu, Winchester, MA (US);
Guo Zhu Zheng, Lexington, MA (US);
Kazunobu Kira, Ibaraki, JP;
Lisa A. Marcaurelle, Arlington, MA (US);
Marta Nevalainen, Weymouth, MA (US);
Ming-Hong Hao, Quincy, MA (US);
Morgan Welzel O'Shea, Arlington, MA (US);
Parcharee Tivitmahaisoon, Boston, MA (US);
Sudeep Prajapati, Somerville, MA (US);
Tuoping Luo, Newton, MA (US);
Nicholas C. Gearhart, Durango, CO (US);
Jason T. Lowe, East Bridgewater, MA (US);
Yoshihiko Kotake, Ibaraki, JP;
Satoshi Nagao, Ibaraki, JP;
Regina Mikie Kanada Sonobe, İbaraki, JP;
Masayuki Miyano, İbaraki, JP;
Norio Murai, Ibaraki, JP;
Andrew Cook, Stow, MA (US);
Shelby Ellery, Boston, MA (US);
Atsushi Endo, Andover, MA (US);
James Palacino, Wellesley, MA (US);
Dominic Reynolds, Stoneham, MA (US);
Eisai R & D Management Co., Ltd., Tokyo, JP;
Abstract
The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.